LACTEL 65:35 DL-PLG (B6001-1) is an amorphous biomedical copolymer of 65 mol% DL-lactide and 35 mol% glycolide, supplied as a white to off-white granular solid. The B6001-1 designation identifies an acid-capped polymer within the 0.55–0.75 dL/g inherent-viscosity grade. Because the DL-lactide repeat unit is heavier than the glycolide repeat unit, the 65:35 molar ratio corresponds to approximately 70:30 by mass. The polymer is not a finished implant; it is a raw material for solvent-based microspheres, solid implants, coatings, scaffolds, and conjugated polymer intermediates. The material is normally handled under ISO 13485-aligned pharmaceutical excipient controls, and the certificate of analysis, not the catalog description, governs lot release.

Which release limits for inherent viscosity, residual monomer, moisture, and metal residues apply before processing?

Control of B6001-1 begins with properties that alter hydrolysis, thermal stability, and processing consistency. Inherent viscosity is measured in chloroform at 30 °C at a concentration of 0.5 g/dL; direct comparison with values obtained in hexafluoroisopropanol or tetrahydrofuran is not valid. The following table lists representative release windows for this acid-capped 65:35 PLG grade; exact lot-specific values must be read from the manufacturer certificate of analysis.

The moisture limit is process-critical: water at levels above 0.5% hydrolyzes the polyester during melt feeding and can reduce molecular weight before the polymer reaches the die. Residual monomer above 1.0% acts as a plasticizer, lowers the glass transition, and has been associated with elevated burst release in microsphere formulations. Tin residues above 150 ppm may alter degradation kinetics and appear in risk assessments under ISO 10993. When lot-specific data are absent, published data for this exact B6001-1 configuration are limited; the table reflects the LACTEL 65:35 acid-terminated class rather than a substitute for a release certificate.

On solvent-based microsphere lines, B6001-1 is dissolved in dichloromethane at 5–20% w/w, filtered through a 0.2 µm PTFE membrane, and emulsified with an aqueous continuous phase containing 0.5–1.0% w/w poly(vinyl alcohol) or equivalent stabilizer. A high-shear mixer operating at 3,000–10,000 rpm creates the dispersed phase; median particle size depends more strongly on rotor-stator geometry and continuous-phase viscosity than on polymer inherent viscosity alone. The extraction bath is held at 2–8 °C to slow phase inversion and reduce surface porosity. Rapid dichloromethane removal at bath temperatures above 15 °C can produce hollow, porous microspheres with lower encapsulation efficiency for low-molecular-weight hydrophobic actives. Residual dichloromethane is then reduced below the ICH Q3C Option 2 limit by vacuum drying or lyophilization at product temperatures below 25 °C.

For melt-extruded or molded forms, pre-drying at 25–35 °C under vacuum for 12–24 h is required when ambient relative humidity exceeds 60%. A co-rotating twin-screw extruder with an L/D of 24:1 or higher and zone temperatures between 130 °C and 160 °C can process the grade, but the acid chain ends and residual moisture make the melt more sensitive to thermal hydrolysis than ester-capped material of the same IV. Residence times above 5 min or local barrel temperatures above 170 °C accelerate random chain scission, lactide reformation, and discoloration. Primary and secondary amines must be excluded from the formulation because nucleophilic attack at the ester linkage causes rapid chain cleavage at processing temperatures.

Spray drying and electrospinning are alternatives for B6001-1 when solvent casting or microspheres are unsuitable. Electrospinning from chloroform/ethanol or hexafluoroisopropanol at polymer concentrations of 10–25% w/w, a voltage of 15–25 kV, and a flow rate of 0.5–2.0 mL/h creates nonwoven mats; residual solvent must be verified against ICH Q3C before biological use. Spray-dried amorphous dispersions are less commonly reported for this exact grade; feasibility should be gated by differential scanning calorimetry and residual solvent testing rather than assumed from other 65:35 PLGAs.

Applications are dominated by parenteral drug delivery because the degradation products DL-lactate and glycolate are metabolized by endogenous pathways. In microsphere formulations, B6001-1 is used for peptide and small-molecule encapsulation where intermediate release from weeks to a few months is required. For implantable coatings, lower solution viscosity than 85:15 PLGA aids spraying, but the acid-capped end group increases water uptake in thin films and can accelerate delamination if the substrate is not primed. In porous scaffold fabrication, the 65:35 ratio provides a compromise between mechanical stiffness and degradation rate, but compressive modulus is low after hydration and should be measured according to ASTM D695 or ISO 604 on finished scaffolds.

When 65:35 DL-PLG replaces a 50:50 grade in a drug-eluting implant

The 65:35 copolymer hydrates more slowly than a 50:50 DL-PLG of similar IV because the higher lactide content reduces the density of hydrophilic glycolide sequences. This shifts degradation from rapid bulk hydrolysis to a more gradual erosion profile and usually delays the onset of mass loss in phosphate-buffered saline at 37 °C and pH 7.4. Release of a small-molecule drug from a B6001-1 matrix is therefore not simply diffusion-controlled over the first days; it becomes increasingly modulated by polymer erosion after the initial diffusion phase. The acid-capped chain ends in B6001-1 partially offset the hydrophobic lactide shift: they increase hydrophilicity at the chain ends and accelerate early water uptake relative to an ester-capped 65:35 grade.

These comparisons are geometry-dependent and are not intrinsic release specifications. A microsphere below 10 µm degrades faster than a dense rod of the same polymer, and autocatalysis in large devices can invert the expected time to mass loss. Lot-to-lot IV variation within the 0.55–0.75 dL/g window can shift release time by a measurable margin; blending high-IV and low-IV lots before dissolution is therefore common during scale-up to reduce inter-lot mobile-phase viscosity differences.

Storage, terminal sterilization, and incompatibility boundaries for B6001-1

B6001-1 should be stored in sealed foil-laminate bags with desiccant at -20 °C or lower. Repeated warming to ambient temperature for dispensing should be conducted in a dry glovebox with a dew point below -40 °C or under inert gas to avoid condensation. Exposure to ambient moisture is not immediately catastrophic, but cumulative moisture uptake reduces IV and shifts release in subsequent processing. Strong alkaline conditions above pH 8 accelerate ester hydrolysis; formulation with amine-rich peptides, amino sugars, or basic drugs can produce premature chain scission unless the API is separated from the polymer or the matrix is neutralized.

Terminal sterilization of the raw polymer or final device imposes additional constraints. Ethylene oxide exposure below 40 °C followed by vacuum degassing is usually less damaging than high-energy radiation, but residual ethylene oxide must meet ISO 10993-7 or ISO 11135 limits. Gamma radiation at 25 kGy causes measurable molecular-weight loss in PLGA; irradiation at dry-ice temperature can reduce radical chain scission but must be validated because the amorphous matrix still undergoes backbone cleavage. Electron-beam irradiation produces similar chain-scission effects and should be evaluated by USP 911 before release. The end-user is responsible for sterility assurance to ISO 11137 or ISO 11135, as applicable, and for cytotoxicity testing on the processed device according to ISO 10993-5.

The terminal carboxylic acid groups of B6001-1 allow carbodiimide-mediated coupling to amine-functionalized poly(ethylene glycol), peptides, or targeting ligands under anhydrous conditions. This conjugation route is not available to ester-capped grades without an additional functionalization step. Reactions should be run in dry dichloromethane or dimethylformamide at 0–8 °C to limit side reactions; published data for this specific B6001-1 conjugate configuration are limited, and end-group conversion should be confirmed by titration, NMR, or GPC before use.